Benutzer: Gast  Login
Titel:

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).

Dokumenttyp:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Article
Autor(en):
Krönke, J; Kuchenbauer, F; Kull, M; Teleanu, V; Bullinger, L; Bunjes, D; Greiner, A; Kolmus, S; Köpff, S; Schreder, M; Mügge, L-O; Straka, C; Engelhardt, M; Döhner, H; Einsele, H; Bassermann, F; Bargou, R; Knop, S; Langer, C
Abstract:
Lenalidomide is an immunomodulatory compound with high clinical activity in multiple myeloma. Lenalidomide binding to the Cereblon (CRBN) E3 ubiquitin ligase results in targeted ubiquitination and degradation of the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) leading to growth inhibition of multiple myeloma cells. Recently, Basigin (BSG) was identified as another protein regulated by CRBN that is involved in the activity of lenalidomide. Here, we analyzed the prognostic valu...     »
Zeitschriftentitel:
Leukemia
Jahr:
2017
Band / Volume:
31
Heft / Issue:
6
Seitenangaben Beitrag:
1363-1367
Sprache:
eng
Volltext / DOI:
doi:10.1038/leu.2016.384
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/28017969
Print-ISSN:
0887-6924
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX